$1.67
+0.08 (+5.03%)
Open$1.61
Previous Close$1.59
Day High$1.71
Day Low$1.60
52W High$49.12
52W Low$24.36
Volume—
Avg Volume282.5K
Market Cap156.20M
P/E Ratio43.74
EPS$0.82
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+2,682.0% upside
Current
$1.67
$1.67
Target
$46.46
$46.46
$33.82
$46.46 avg
$60.35
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.58M | 13.34M | 13.91M |
| Net Income | 2.88M | 3.22M | 3.61M |
| Profit Margin | 19.8% | 24.2% | 26.0% |
| EBITDA | 4.55M | 4.43M | 4.67M |
| Free Cash Flow | 4.06M | 3.77M | 3.36M |
| Rev Growth | -8.4% | -7.1% | -8.2% |
| Debt/Equity | 0.65 | 0.58 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |